<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74000">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02077543</url>
  </required_header>
  <id_info>
    <org_study_id>ProTool</org_study_id>
    <nct_id>NCT02077543</nct_id>
  </id_info>
  <brief_title>Multicenter Safety Trial Assessing an Innovative Tumor Molecular and Cellular Print Medical Device in Glioma</brief_title>
  <acronym>ProTool</acronym>
  <official_title>Molecular and Cellular Print Medical Device Validation in Adult Glioma Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the innocuity and operability of the innovative
      tumor molecular and cellular print ProTool.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diagnostic in cancerology keeps based on biopsy or exeresis tissues anatomopathologic
      analysis. Micro-invasive biopsy approaches reduces chirurgical aggressivity but also tissue
      amount The innovative Medical Device ProTool offers a micro-invasive biopsy approach in
      parallel with classical chirurgical proceeding. It allows to complete heterogeneity tumoral
      analysis and peri-tumoral tissue environment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Clinical examination : neurologic deficiency, allergic reaction, infections, pain, headaches, others adverse events... Postoperative MRI evaluation : no hematoma</measure>
    <time_frame>2 hours after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical examination : neurologic deficiency, allergic reaction, infections, pain, headaches, others adverse events... Postoperative MRI evaluation : no hematoma</measure>
    <time_frame>one month after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical examination : neurologic deficiency, allergic reaction, infections, pain, headaches, others adverse events... Postoperative MRI evaluation : no hematoma</measure>
    <time_frame>3 months after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular measurements in intra-operative cellular samples : transcriptome, micro-RNA, proteome and cellular cultur analysis</measure>
    <time_frame>up to 1 month after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Glioma : Oligodendroglioma or Astrocytoma</condition>
  <arm_group>
    <arm_group_label>ProTool</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device:   Molecular and cellular tumor print Medical Device (ProTool)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Molecular and cellular tumor print Medical Device (ProTool)</intervention_name>
    <description>Proteomic, genomic and cellular culture</description>
    <arm_group_label>ProTool</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  more or equal than 18 years old

          -  patient affiliated to social security or similarly regime

          -  informed consent form signed

          -  glial tumor suspicion

          -  Stereotaxic biopsy indication

          -  Karnofsky score &gt; 70%

          -  Hematological assessment :

          -  neutrophils &gt; 1500/mm3

          -  Platelet  &gt; 150 000

          -  blood Creatinin normal

          -  alkaline Phosphatases and transaminases no more than two times normal

          -  Bilirubin &lt; 1.5 times normal

        Exclusion Criteria:

          -  Pregnant women and lactating mothers

          -  Ward of court or under guardianship

          -  Adult unable to express their consent

          -  Person deprived of freedom by judicial or administrative decision

          -  Person hospitalized without their consent

          -  Person under legal protection

          -  Person participating in another clinical study

          -  Intratumoral hemorrhage MRI detected

          -  Treatment anticoagulant or antisludge treatments

          -  Active Infections and non controled or medical affection or psychiatric intercurrent
             non treated

          -  Evolutive cerebral oedema without corticoid response

          -  Non controled Epilepsy without antiepileptics response

          -  Susceptibility to Medical Device materials allergy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François BERGER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Grenoble Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François BERGER, MD, PhD</last_name>
    <phone>+ 33 4 38 78 15 18</phone>
    <email>francois.berger@cea.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline SANDRE-BALLESTER, PhD</last_name>
    <phone>+ 33 4 38 78 28 51</phone>
    <email>csandreballester@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Angers University Hospital</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe MENEI, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Caroline SANDRE-BALLESTER, PhD</last_name>
      <phone>+33 4 38 78 28 51</phone>
    </contact_backup>
    <investigator>
      <last_name>Philippe MENEI, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henri Mondor University Hospital</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane PALFI, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Caroline SANDRE-BALLESTER, PhD</last_name>
      <phone>+33 4 38 78 28 51</phone>
      <email>csandreballester@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Stéphane PALFI, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CLINATEC</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François , MD, PhD</last_name>
      <email>francois.berger@cea.fr</email>
    </contact>
    <contact_backup>
      <last_name>Caroline SANDRE-BALLESTER, PhD</last_name>
      <email>csandreballester@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>François BERGER, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel GAY, MD, PhD</last_name>
      <email>EGay@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Caroline SANDRE-BALLESTER, PhD</last_name>
      <phone>+33 4 38 78 28 51</phone>
      <email>csandreballester@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Emmanuel GAY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sainte-Anne Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand DEVAUX, Pr</last_name>
    </contact>
    <contact_backup>
      <last_name>Caroline SANDRE-BALLESTER, PhD</last_name>
      <phone>+33 4 38 78 28 51</phone>
      <email>csandreballester@chu-grenoble.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 28, 2014</lastchanged_date>
  <firstreceived_date>October 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
